Mizuho raises Cardinal Health stock price target on strong pharma growth

Mizuho raised its Cardinal Health price target to $290 from $280 and lifted fiscal 2027 and 2028 EPS estimates to $13.00 and $14.75, respectively, citing pharmaceutical growth and new products. Separately, fiscal Q1 adjusted EPS of $3.26 beat the $2.95 estimate, revenue of $67.5B topped the $66.59B forecast, and the company raised full-year EPS guidance to $12.80–$13.00. Higher petroleum costs are pushing fiscal 2027 medical products distribution EBIT toward the low end of its $200M–$220M guidance.

Analysis

CAH’s earnings leverage is increasingly tied to specialty and new-product mix, not simply distribution volume. That makes the upside case more durable if those products sustain growth—but also raises the risk that investors extrapolate a favorable mix shift before the 18-month launch pipeline is proven. The reported revenue beat is less informative than gross-profit conversion and operating leverage in a low-margin distribution model. High petroleum costs are a counterweight concentrated in medical products distribution; they could limit consolidated upside without invalidating the pharmaceutical thesis.

Near term, the main risk is a “good news, already priced” reaction: shares are near their 52-week high, and the analyst’s $290 target implies limited upside from the cited $271 price. Over 1–3 months, track estimate revisions and whether guidance holds at the upper end; over 6–18 months, verify launches translate into incremental gross profit rather than being offset by generic pricing or procurement pressure. Red Oak’s eventual extension terms could affect generic economics, while customer channel shifts under 340B may change volume without guaranteeing attractive margins. The contrarian point: headline sales growth can obscure whether earnings quality is improving; gross profit, segment EBIT, and cash conversion matter more.

Key Decisions for Investors

• Do not chase the near-high print. Existing holders can retain exposure, but add only on weakness or after another quarter confirms gross-profit growth and cash conversion; the cited analyst target offers limited near-term room.
• Use estimate revisions and FY27 guidance as the 1–3 month catalysts. Reassess the long thesis if management cuts its $12.80–$13.00 FY27 EPS outlook or pharmaceutical gross-profit growth decelerates.
• Treat CAH as a selective earnings-quality long, not a broad healthcare-distribution rerating. Watch whether high-teens specialty growth and upcoming products produce incremental segment profit; defer a relative-value trade versus McKesson or Cencora until comparable valuation and segment data are verified.
• Monitor petroleum costs, Red Oak extension terms, and 340B-related channel mix. A sustained cost drag or volume growth that fails to convert into gross profit would weaken the thesis even if reported revenue remains strong.